MK-4827 tosylate is primarily used in cancer research and therapy development due to its potent inhibition of PARP enzymes, specifically PARP-1 and PARP-2. By blocking these enzymes, it interferes with DNA repair mechanisms in cancer cells, especially those already deficient in repair pathways such as BRCA-mutated cells. This leads to selective cancer cell death through a mechanism known as synthetic lethality. It has shown promising activity in preclinical and clinical studies for treating solid tumors, including ovarian, breast, and prostate cancers. Its use is being explored both as a monotherapy and in combination with DNA-damaging agents like chemotherapy or radiation to enhance antitumor effects. Due to its targeted action, MK-4827 tosylate represents a key compound in the development of precision oncology treatments.